BioCentury | Jun 30, 2014
Clinical News

Treanda regulatory update

...to the product in Japan, South Korea and Singapore to Eisai and in Taiwan to InnoPharmax...
...cell NHL. Mundipharma markets it as Ribomustin in Germany to treat CLL, NHL and MM. InnoPharmax Inc....
BioCentury | Dec 9, 2013
Clinical News

Treanda endamustine regulatory update

...to the product in Japan, South Korea and Singapore to Eisai and in Taiwan to InnoPharmax...
...Switzerland), co-market rituximab as Rituxan in the U.S., while Roche markets it as MabThera elsewhere. InnoPharmax Inc....
BioCentury | Nov 18, 2013
Clinical News

Treakisym bendamustine: Phase II discontinued

...to the product in Japan, South Korea and Singapore to Eisai and in Taiwan to InnoPharmax...
...cell NHL. Mundipharma markets it as Ribomustin in Germany to treat CLL, NHL and MM. InnoPharmax Inc....
BioCentury | Sep 23, 2013
Clinical News

Treanda regulatory update

...to the product in Japan, South Korea and Singapore to Eisai and in Taiwan to InnoPharmax...
...Mundipharma markets it as Ribomustin in Germany to treat CLL, NHL and multiple myeloma (MM). InnoPharmax Inc....
BioCentury | May 20, 2013
Clinical News

Treanda: Phase II started

...to the product in Japan, South Korea and Singapore to Eisai and in Taiwan to InnoPharmax...
...Mundipharma markets it as Ribomustin in Germany to treat CLL, NHL and multiple myeloma (MM). InnoPharmax Inc....
BioCentury | Mar 25, 2013
Clinical News

Treanda bendamustine regulatory update

...to the product in Japan, South Korea and Singapore to Eisai and in Taiwan to InnoPharmax...
...Switzerland), co-market rituximab as Rituxan in the U.S., while Roche markets it as MabThera elsewhere. InnoPharmax Inc....
BioCentury | Mar 11, 2013
Clinical News

Treakisym bendamustine: Completed Phase II enrollment

...to the product in Japan, South Korea and Singapore to Eisai and in Taiwan to InnoPharmax...
...Switzerland), co-market rituximab as Rituxan in the U.S., while Roche markets it as MabThera elsewhere. InnoPharmax Inc....
BioCentury | Mar 4, 2013
Clinical News

Bendamustine: Updated Phase III data

...to the product in Japan, South Korea and Singapore to Eisai and in Taiwan to InnoPharmax...
...Switzerland), co-market rituximab as Rituxan in the U.S., while Roche markets it as MabThera elsewhere. InnoPharmax Inc....
BioCentury | Jan 28, 2013
Clinical News

Bendamustine: Phase II start

...to the product in Japan, South Korea and Singapore to Eisai and in Taiwan to InnoPharmax...
...Mundipharma markets it as Ribomustin in Germany to treat CLL, NHL and multiple myeloma (MM). InnoPharmax Inc....
BioCentury | Oct 29, 2012
Clinical News

Bendamustine regulatory update

...market the product in Japan, South Korea and Singapore to Eisai and in Taiwan to InnoPharmax...
...Switzerland), co-market rituximab as Rituxan in the U.S., while Roche markets it as MabThera elsewhere. InnoPharmax Inc....
Items per page:
1 - 10 of 27
BioCentury | Jun 30, 2014
Clinical News

Treanda regulatory update

...to the product in Japan, South Korea and Singapore to Eisai and in Taiwan to InnoPharmax...
...cell NHL. Mundipharma markets it as Ribomustin in Germany to treat CLL, NHL and MM. InnoPharmax Inc....
BioCentury | Dec 9, 2013
Clinical News

Treanda endamustine regulatory update

...to the product in Japan, South Korea and Singapore to Eisai and in Taiwan to InnoPharmax...
...Switzerland), co-market rituximab as Rituxan in the U.S., while Roche markets it as MabThera elsewhere. InnoPharmax Inc....
BioCentury | Nov 18, 2013
Clinical News

Treakisym bendamustine: Phase II discontinued

...to the product in Japan, South Korea and Singapore to Eisai and in Taiwan to InnoPharmax...
...cell NHL. Mundipharma markets it as Ribomustin in Germany to treat CLL, NHL and MM. InnoPharmax Inc....
BioCentury | Sep 23, 2013
Clinical News

Treanda regulatory update

...to the product in Japan, South Korea and Singapore to Eisai and in Taiwan to InnoPharmax...
...Mundipharma markets it as Ribomustin in Germany to treat CLL, NHL and multiple myeloma (MM). InnoPharmax Inc....
BioCentury | May 20, 2013
Clinical News

Treanda: Phase II started

...to the product in Japan, South Korea and Singapore to Eisai and in Taiwan to InnoPharmax...
...Mundipharma markets it as Ribomustin in Germany to treat CLL, NHL and multiple myeloma (MM). InnoPharmax Inc....
BioCentury | Mar 25, 2013
Clinical News

Treanda bendamustine regulatory update

...to the product in Japan, South Korea and Singapore to Eisai and in Taiwan to InnoPharmax...
...Switzerland), co-market rituximab as Rituxan in the U.S., while Roche markets it as MabThera elsewhere. InnoPharmax Inc....
BioCentury | Mar 11, 2013
Clinical News

Treakisym bendamustine: Completed Phase II enrollment

...to the product in Japan, South Korea and Singapore to Eisai and in Taiwan to InnoPharmax...
...Switzerland), co-market rituximab as Rituxan in the U.S., while Roche markets it as MabThera elsewhere. InnoPharmax Inc....
BioCentury | Mar 4, 2013
Clinical News

Bendamustine: Updated Phase III data

...to the product in Japan, South Korea and Singapore to Eisai and in Taiwan to InnoPharmax...
...Switzerland), co-market rituximab as Rituxan in the U.S., while Roche markets it as MabThera elsewhere. InnoPharmax Inc....
BioCentury | Jan 28, 2013
Clinical News

Bendamustine: Phase II start

...to the product in Japan, South Korea and Singapore to Eisai and in Taiwan to InnoPharmax...
...Mundipharma markets it as Ribomustin in Germany to treat CLL, NHL and multiple myeloma (MM). InnoPharmax Inc....
BioCentury | Oct 29, 2012
Clinical News

Bendamustine regulatory update

...market the product in Japan, South Korea and Singapore to Eisai and in Taiwan to InnoPharmax...
...Switzerland), co-market rituximab as Rituxan in the U.S., while Roche markets it as MabThera elsewhere. InnoPharmax Inc....
Items per page:
1 - 10 of 27